NAD+ depletion in CD8+ T cells triggers mitochondrial dysfunction and cellular senescence, driving a pro-inflammatory state that worsens ulcerative colitis. Senolytic treatment—which clears senescent cells—significantly reduces disease severity, suggesting a direct therapeutic pathway for inflammatory bowel disease.
Key Points
- NAD+ depletion causes mitochondrial DNA leakage, activating inflammatory CD8+ T cells
- Senescent T cells accumulate in intestinal tissue and disrupt the epithelial barrier
- Senolytics reduce colitis severity; senescent signature predicts non-response to biologics
Longevity Analysis
This work identifies a specific metabolic failure—NAD+ dysregulation—as a driver of immune cell aging and chronic intestinal inflammation. Rather than treating inflammation after it develops, the research points to restoring the energy-production capacity of immune cells as a preventive approach. The senescent-metabolic signature also offers a biomarker for predicting which patients will fail standard therapies, shifting treatment from empirical to mechanism-informed. For individuals managing inflammatory bowel disease or seeking to optimize immune resilience, this suggests that NAD+ availability and mitochondrial health in immune tissue directly influence both disease trajectory and treatment response.
Original published by Wiley Aging Cell, by Maolin Ye, Qi Zhou, Mingjia Kong, Suhan Zhao, Lingxi Lin, Lirong Chen, Jianghong Yu, Feifei Luo, Jie Liu, Jun Zhang .